NCT03473236View on ClinicalTrials.gov

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

PHASE1CompletedINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions

Safety Issues

Interventions

DRUG

GB002

Inhaled GB002

DEVICE

Generic Dry Powder Inhaler

dry powder inhaler used for inhalation of active drug or placebo

DRUG

Placebo

Inhaled placebo

Trial Locations (1)

00000

Phase 1 Unit, San Antonio

Sponsors

Collaborators (1)

Worldwide Clinical Trials

All Listed Sponsors

collaborator

Pulmokine Inc.

INDUSTRY

collaborator

Worldwide Clinical Trials

OTHER

lead

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

INDUSTRY